ClinicalTrials.gg
TerminatedNCT01486966Updated Mar 17, 2017Results posted

Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes

A Phase 4 interventional study of insulin detemir and insulin aspart in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Terminated at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-17.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

How we know

Why this study was terminated
Trial terminated prematurely due to slow recruitment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Insulin Detemir · Diabetes Mellitus, Type 2.

Enrollment
29th of 43
58 · median 130
Started
2011
with 1 other
Phase 4
23 of 43
none open now
Registered
37th of 43
by date
Lead sponsor
28 of 43
Novo Nordisk A/S

Among the 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2, this one is the 29th largest by enrollment, is one of 2 that started in 2011, is one of 23 in phase 4, and was the 37th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin Detemir

Insulin Detemir: first FDA approval 2005 (LEVEMIR FLEXTOUCH), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Asia. The aim of this trial is to compare efficacy and safety of insulin detemir plus insulin aspart and NPH insulin plus human soluble insulin both in a basal bolus regimen with or without metformin in Chinese patients with type 2 diabetes.

The trial adopts a group sequential design, where the analysis of the primary efficacy endpoint will be performed at the interim analysis, in addition to the final formal analysis. The decision to continue or stop the trial will be based on the result of the interim analysis.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 58 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus (diagnosed clinically) for at 12 months or longer
  • Currently treated with basal insulin once daily or premixed insulin twice daily for at least 3 months with or without OAD(s), and total daily insulin dose less than 1.4 IU (U)/kg (If treated with metformin, unchanged total daily dose of at least 1000 mg for at least 3 months)
  • (BMI) equal to 40 kg/m\^2 or below
  • (glycosylated haemoglobin A1c) between 7.0% and 10.0% by central laboratory analysis
  • Plan to be admitted for optimising glycaemic control at least 2 days prior to the randomisation

Exclusion criteria

Exclusion Criteria:

  • Treatment with thiazolidinediones (TZD) or Glucagon-Like Peptide-1 (GLP-1) receptor agonists within the last 3 months prior to the screening
  • Anticipated change after the randomisation in concomitant medication known to interfere with glucose metabolism, such as systemic , beta-blockers and mono amine oxidase (MAO) inhibitors
  • Previous participation in this trial (participation is defined as randomised. Re-screening of screening failures is allowed only once within the limits of the recruitment period.)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Insulin detemir / IAsp

    Drug: insulin detemir · Drug: insulin aspart · Drug: metformin

  • Active comparator
    insulin NPH

    Drug: insulin NPH · Drug: human soluble insulin · Drug: metformin

Interventions

  • Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4

  • Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4

  • DrugInsulin, IsophaneStudies of Insulin, IsophaneInsulin, Isophane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4

  • DrugInsulin, Regular, HumanStudies of Insulin, Regular, HumanInsulin, Regular, Human pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4

  • For subjects previously treated with metformin, the dosage and frequency will be kept unchanged

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean 8-point Plasma Glucose (PG) After Two Weeks of Treatment

    Mean value of 8-point PG was the arithmetic mean of all 8 time-instant PG values of the 8-point PG profile.

    Time frame: Week 0, week 2

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG) After Two Weeks of Treatment

    The FPG referred to pre-breakfast plasma glucose.

    Time frame: Week 0, week 2

  2. Change From Baseline in Mean 2-hour Post Prandial Plasma Glucose (2hPPG) of 3 Meals After Two Weeks of Treatment

    The mean 2hPPG was derived from the 8-point PG profile as the mean value of the available 120 minutes after each meal.

    Time frame: Week 0, week 2

  3. Change From Baseline in Mean Value of Pre-lunch, Pre-dinner and Bedtime PG After Two Weeks of Treatment

    The mean value of pre-lunch, pre-dinner and bedtime PG was derived from the 8-point PG profile measured before lunch, dinner and bedtime.

    Time frame: Week 0, week 2

  4. Percentage of Subjects Achieving FPG < 6.0 mmol / L After Two Weeks of Treatment

    Time frame: Week 2

  5. Percentage of Subjects Achieving Mean 2hPPG of 3 Meals < 8.0 mmol / L After Two Weeks of Treatment

    Time frame: Week 2

  6. Percentage of Subjects Achieving Both FPG and 2hPPG Targets After Two Weeks of Treatment

    FPG target was \< 6.0 mmol / L, 2hPPG target was \< 8.0 mmol / L.

    Time frame: Week 2

  7. Percentage of Subjects Achieving FPG Target Without Nocturnal Hypoglycaemia After Two Weeks of Treatment

    FPG target was \< 6.0 mmol / L. Nocturnal hypoglycaemia was defined as a hypoglycaemic episode happened between 00:01 and 05:59 a.m. (both included).

    Time frame: Week 2

  8. Change From Baseline in Fructosamine After Two Weeks of Treatment

    Time frame: Week 0, week 2

  9. Incidence of Hypoglycaemic Episodes

    All events summarized were treatment emergent hypoglycaemic events. Hypoglycaemic episodes were summarized based on the ADA classification and also according to an additional definition. Severe hypoglycemia: ADA definition. Minor hypoglycaemic episode: an episode with symptoms with confirmation by plasma glucose (PG) \< 3.1 mmol/l (56 mg/dl) and was handled by the subject himself/herself, or any asymptomatic PG value \< 3.1 mmol/l (56 mg/dl). A hypoglycaemia episode was defined as nocturnal if the time of onset was between 00:01 and 05:59 a.m. (both included), otherwise it was diurnal.

    Time frame: Weeks 0-2

08

Results

Posted Jun 17, 2013
Limitations and caveats
The size of population analysed in study was smaller than that planned in the protocol. Therefore, the superiority of experimental products to comparator could not be concluded with sufficient statistical power.

Participant flow

A total of 6 centres in China participated.

Participant flow — Overall Study
MilestoneInsulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± Metformin
Started2929
Completed2927
Not completed02
Withdrew: Adverse event01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryChange From Baseline in Mean 8-point Plasma Glucose (PG) After Two Weeks of Treatment

Mean value of 8-point PG was the arithmetic mean of all 8 time-instant PG values of the 8-point PG profile.

Time frame:
Week 0, week 2
Reported as:
Least squares mean · mmol/L
Change From Baseline in Mean 8-point Plasma Glucose (PG) After Two Weeks of Treatment
mmol/LInsulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± Metformin
Change From Baseline in Mean 8-point Plasma Glucose (PG) After Two Weeks of Treatment-2.84 ± 0.27-2.80 ± 0.28
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) After Two Weeks of Treatment

The FPG referred to pre-breakfast plasma glucose.

Time frame:
Week 0, week 2
Reported as:
Least squares mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG) After Two Weeks of Treatment
mmol/LInsulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± Metformin
Change From Baseline in Fasting Plasma Glucose (FPG) After Two Weeks of Treatment-2.22 ± 0.34-2.29 ± 0.35
SecondaryChange From Baseline in Mean 2-hour Post Prandial Plasma Glucose (2hPPG) of 3 Meals After Two Weeks of Treatment

The mean 2hPPG was derived from the 8-point PG profile as the mean value of the available 120 minutes after each meal.

Time frame:
Week 0, week 2
Reported as:
Least squares mean · mmol/L
Change From Baseline in Mean 2-hour Post Prandial Plasma Glucose (2hPPG) of 3 Meals After Two Weeks of Treatment
mmol/LInsulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± Metformin
Change From Baseline in Mean 2-hour Post Prandial Plasma Glucose (2hPPG) of 3 Meals After Two Weeks of Treatment-4.00 ± 0.39-3.47 ± 0.40
SecondaryChange From Baseline in Mean Value of Pre-lunch, Pre-dinner and Bedtime PG After Two Weeks of Treatment

The mean value of pre-lunch, pre-dinner and bedtime PG was derived from the 8-point PG profile measured before lunch, dinner and bedtime.

Time frame:
Week 0, week 2
Reported as:
Least squares mean · mmol/L
Change From Baseline in Mean Value of Pre-lunch, Pre-dinner and Bedtime PG After Two Weeks of Treatment
mmol/LInsulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± Metformin
Change From Baseline in Mean Value of Pre-lunch, Pre-dinner and Bedtime PG After Two Weeks of Treatment-2.47 ± 0.38-2.87 ± 0.38
SecondaryPercentage of Subjects Achieving FPG < 6.0 mmol / L After Two Weeks of Treatment
Time frame:
Week 2
Reported as:
Number · percentage (%) of subjects
Percentage of Subjects Achieving FPG < 6.0 mmol / L After Two Weeks of Treatment
percentage (%) of subjectsInsulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± Metformin
Percentage of Subjects Achieving FPG < 6.0 mmol / L After Two Weeks of Treatment48.348.3
SecondaryPercentage of Subjects Achieving Mean 2hPPG of 3 Meals < 8.0 mmol / L After Two Weeks of Treatment
Time frame:
Week 2
Reported as:
Number · percentage (%) of subjects
Percentage of Subjects Achieving Mean 2hPPG of 3 Meals < 8.0 mmol / L After Two Weeks of Treatment
percentage (%) of subjectsInsulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± Metformin
Percentage of Subjects Achieving Mean 2hPPG of 3 Meals < 8.0 mmol / L After Two Weeks of Treatment41.434.5
SecondaryPercentage of Subjects Achieving Both FPG and 2hPPG Targets After Two Weeks of Treatment

FPG target was \< 6.0 mmol / L, 2hPPG target was \< 8.0 mmol / L.

Time frame:
Week 2
Reported as:
Number · percentage (%) of subjects
Percentage of Subjects Achieving Both FPG and 2hPPG Targets After Two Weeks of Treatment
percentage (%) of subjectsInsulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± Metformin
Percentage of Subjects Achieving Both FPG and 2hPPG Targets After Two Weeks of Treatment20.720.7
SecondaryPercentage of Subjects Achieving FPG Target Without Nocturnal Hypoglycaemia After Two Weeks of Treatment

FPG target was \< 6.0 mmol / L. Nocturnal hypoglycaemia was defined as a hypoglycaemic episode happened between 00:01 and 05:59 a.m. (both included).

Time frame:
Week 2
Reported as:
Number · percentage (%) of subjects
Percentage of Subjects Achieving FPG Target Without Nocturnal Hypoglycaemia After Two Weeks of Treatment
percentage (%) of subjectsInsulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± Metformin
Percentage of Subjects Achieving FPG Target Without Nocturnal Hypoglycaemia After Two Weeks of Treatment41.434.5
SecondaryChange From Baseline in Fructosamine After Two Weeks of Treatment
Time frame:
Week 0, week 2
Reported as:
Least squares mean · Umol/L
Change From Baseline in Fructosamine After Two Weeks of Treatment
Umol/LInsulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± Metformin
Change From Baseline in Fructosamine After Two Weeks of Treatment-31.0 ± 5.37-23.7 ± 5.50
SecondaryIncidence of Hypoglycaemic Episodes

All events summarized were treatment emergent hypoglycaemic events. Hypoglycaemic episodes were summarized based on the ADA classification and also according to an additional definition. Severe hypoglycemia: ADA definition. Minor hypoglycaemic episode: an episode with symptoms with confirmation by plasma glucose (PG) \< 3.1 mmol/l (56 mg/dl) and was handled by the subject himself/herself, or any asymptomatic PG value \< 3.1 mmol/l (56 mg/dl). A hypoglycaemia episode was defined as nocturnal if the time of onset was between 00:01 and 05:59 a.m. (both included), otherwise it was diurnal.

Time frame:
Weeks 0-2
Reported as:
Number · events
Incidence of Hypoglycaemic Episodes
eventsInsulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± Metformin
All events2254
Severe00
Nocturnal411
Diurnal1843
Minor211

Adverse events

Collected over The adverse events were collected in a timeframe of 2 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Detemir + Insulin Aspart ± Metformin—0/29 (0%)0/29 (0%)
Insulin NPH + Human Soluble Insulin ± Metformin—0/29 (0%)2/29 (6.9%)
Most frequent other events
Most frequent other events
EventInsulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± Metformin
upper restiratory tract infectionInfections and infestations0/292/29

Baseline characteristics

Age, Continuous
Age, Continuous(years)Insulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± MetforminTotal
Mean57.6 ± 10.255.8 ± 9.856.7 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± MetforminTotal
Female141529
Male151429
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± MetforminTotal
American Indian or Alaska Native000
Asian292958
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Height
Height(cm)Insulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± MetforminTotal
Mean164.2 ± 8.5164.2 ± 8.4164.2 ± 8.4
Weight
Weight(kg)Insulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± MetforminTotal
Mean70.9 ± 13.166.5 ± 9.068.7 ± 11.4
Body mass index (BMI)
Body mass index (BMI)(kg/m^2)Insulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± MetforminTotal
Mean26.09 ± 3.1324.63 ± 2.6725.36 ± 2.98
Pre-trial treatment of oral antidiabetic drug
Pre-trial treatment of oral antidiabetic drug(participants)Insulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± MetforminTotal
Acarbose91019
Gliclazide033
Glimepiride246
Metformin13821
Metformin hydrochloride235
Repaglinide224
Pre-trial insulin treatment
Pre-trial insulin treatment(participants)Insulin Detemir + Insulin Aspart ± MetforminInsulin NPH + Human Soluble Insulin ± MetforminTotal
basal insulin (once daily)6713
premixed insulin (twice daily)232245

4 further baseline measures are reported on the registry.

09

Study locations

6 sites
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100034, China
  • Novo Nordisk Investigational Site
    Chongqing, Chongqing 400016, China
  • Novo Nordisk Investigational Site
    Wuxi, Jiangsu 214023, China
  • Novo Nordisk Investigational Site
    Nanchang, Jiangxi 330006, China
  • Novo Nordisk Investigational Site
    Shanghai, Shanghai 200003, China
  • Novo Nordisk Investigational Site
    Shanghai, Shanghai 200072, China
10

References and documents

Publications

  • Guo X, Li Q, Shi Y, Bu R, Liu J, Qu S, Gao Y. Efficacy and safety of insulin detemir plus insulin aspart versus NPH insulin plus human soluble insulin with or without metformin in Chinese type 2 diabetes. Chinese J Diabetes 2014; 22 (1)
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2011
First posted
Dec 7, 2011
Start
Nov 2011
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Jun 17, 2013
Last update
Mar 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01486966
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 7, 2011
Start date
Nov 2011
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Jun 17, 2013
Last update
Mar 17, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Detemir · Insulin Aspart

Start the discussion